跳至主要内容
临床试验/DRKS00011489
DRKS00011489已完成不适用

RAD327 Lu-177 Dosimetry with SPECT/CT - RAD327 COMPARE PRRT

niversitätsklinikum Magdeburg0 个研究点目标入组 6 人开始时间: 2017年7月19日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
6

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 Years 至 one(—)
性别
All

入选标准

  • Indication for Lutetium-177-DOTATATE therapy
  • - by minimum two successfully performed therapy cycles
  • - age > 18 years
  • - normal renal function
  • - no contraindication for the second examinations (e.g. claustrophobia, poor general condition)

排除标准

  • Missing compliance to the additional examinations

研究者

发起方
niversitätsklinikum Magdeburg

相似试验

招募中
早期 1 期
177Lu-P17-087/177Lu-P17-088 in Patients With Metastatic Castration-resistant Prostate CancerMetastatic Castration-resistant Prostate Cancer
NCT05603559Peking Union Medical College Hospital30
进行中(未招募)
不适用
Receptorial radiotherapy with 177Lu DOTATATE in somatostatine receptors positive tumours, a phase II study.cancer patientsMedDRA version: 14.1Level: HLGTClassification code 10014713Term: Endocrine neoplasms malignant and unspecifiedSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2011-002891-18-ITISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI
招募中
4 期
Measurement of safety limit of radionuclide therapy in treatment of patients with prostate cancer
CTRI/2016/06/006998All India Institute of Medical Sciences50
进行中(未招募)
不适用
Receptorial radiotherapy with 177Lu-DOTA-Tyr3-Octreotate as Maintaining Therapy in Extended Small Cell Lung Cancer (SCLC) after a first standard chemotherapy line - IRST162.02oncological patientsMedDRA version: 12.1Level: LLTClassification code 10026532Term: Malignant neoplasm of thorax
EUCTR2010-018333-21-ITISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI
招募中
1 期
Therapy with radiopharmaceutical 177Lu-DOTATOC (177Lu-edotreotide or 177Lu-octreotide) in patients with diagnosis of somatostatin receptor positive tumor: a multicenter, prospective phase 2 studyPatients must have histologically or cytologically confirmation of neuroendocrine tumors or any other tumor histotype documented as sst-positiveMedDRA version: 20.0Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
EUCTR2023-000086-14-ITISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI (IRST) S.R.L. IRCCS268